Jbt Marel vs nVent Electric
JBTM and NVT side by side, both in special industry machinery, except metalworking. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JBTM and NVT compare
nVent Electric is the larger company, worth 3.6 times as much as Jbt Marel ($20.4B against $5.7B).
On earnings, Jbt Marel is cheaper: it trades at 29.7× trailing earnings, against 30.4× for nVent Electric.
nVent Electric grew revenue faster over the last twelve months (48.0% versus 44.9% for Jbt Marel).
nVent Electric keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with 4.9% at Jbt Marel.
Both pay dividends: Jbt Marel yields 0.37% and nVent Electric 0.50%.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JBTM | NVT |
|---|---|---|
| Size and price | ||
| Market cap | $5.7B | $20.4B |
| Share price | $109.17 | $125.98 |
| Change, 1 year | −12.9% | 18.5% |
| Change, 5 years | −34.0% | 239% |
| Beta (5Y) | 1.00 | 1.30 |
| Employees | 12K | 12K |
| StockData Score | ||
| Total score | 13 | 13 |
| Valuation score | 3 (better) | 1 |
| Growth score | 2 | 4 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 4 (better) | 3 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 29.7× (better) | 30.4× |
| P/S | 1.4× (better) | 3.9× |
| P/B | 1.3× | – |
| EV/EBITDA | 25.1× | 22.8× (better) |
| P/FCF | 18.3× (better) | 31.7× |
| PEG | – | 1.39 |
| FCF yield | 5.5% (better) | 3.2% |
| Fair value | $115.53 | $119.23 |
| Margin of safety | 5.5% (better) | −5.7% |
| Growth | ||
| Revenue growth (TTM) | 44.9% | 48.0% (better) |
| Revenue growth, 5Y average | 17.1% (better) | 14.3% |
| Net income growth (TTM) | – | 12.9% |
| EPS growth (TTM) | – | 14.0% |
| Profitability | ||
| Gross margin | 35.6% | 36.6% (better) |
| Operating margin | 7.3% | 17.8% (better) |
| Net margin | 4.9% | 12.8% (better) |
| FCF margin | 7.9% | 12.1% (better) |
| Return on equity | 4.3% | – |
| Return on invested capital | 3.8% | – |
| Financial health | ||
| Debt / equity | 0.38 | – |
| Net debt / EBITDA | 5.46 | 1.12 (better) |
| Current ratio | 1.24 | 2.40 (better) |
| Altman Z-score | 1.88 | 4.73 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.37% | 0.50% (better) |
| Payout ratio | 10.9% | 19.8% |
| Years of dividend growth | 0 | 2 (better) |
| Dividend growth, 5Y average | 0.00% | 2.7% (better) |
| Buyback yield | – | 0.49% |
| Shareholder yield | 0.37% | 0.99% (better) |
| Ownership | ||
| Held by institutions | 103% | 91.0% |
| Held by insiders | 1.4% | 0.80% |
| Insider net buying, 12 months | −$7.2M (better) | −$51.1M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.1% | 3.0% |
Go deeper
- JBTM stock overview
- JBTM income statement
- JBTM valuation and score
- NVT stock overview
- NVT income statement
- NVT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.